

Vietnam: Banking 20 October 2020

BUY

TP upside (downside) -8% Close 19 Oct 2020

Price VND 14,100 12M Target VND 12,950

Share price performance relative to VNI



Source: Bloomberg

Market cap	US\$1.1 bn
6M avg. daily turnover	US\$6.4 mn
Outstanding shares	1,804 mn
Free float	95%
FINI ownership	9.2%
Major shareholders	15%
2020E Asset/Equity (*)	16.8x
2020E P/E (*)	10.7x
2020E P/B (*)	0.9x
FOL Remaining Room	14.4%
2020E Dividend yield (*)	0.0%

Source: FiinPro, (*) Yuanta Vietnam

Research Analyst:

Tanh Tran

+84 28 3622 6868 ext 3874

tanh.tran@yuanta.com.vn

Bloomberg code: YUTA

SACOMBANK (STB VN)

Higher provision hurt earnings

Event

STB reported 3Q20 PATMI of VND716 tn (+109% QoQ but -7% YoY). Higher net interest income and net fee income helped boost PPOP, while increased provisions dented earnings. In 9M20, STB's PATMI was VND1.8 tn (-4% YoY), fulfilling 91% of our forecast for 2020E.

Details

Loans increased by 8% YTD, completing 66% of our 2020E forecast.

3Q20 net interest income was VND3.0 tn (+15% QoQ/+4% YoY). NIM on total average assets was 2.51% in 3Q20 (+27bps QoQ/-12bps YoY), which we attribute to slightly lower funding costs due to <u>SBV</u> easing.

3Q20 net fee income jumped by +79% QoQ/ +67% YoY to reach VND1.2 tn. Other income (mostly loan loss recoveries) soared by 225% QoQ/+213% YoY to reach VND358 bn.

Provisioning was VND1.3 tn in 3Q20 (+12% QoQ/+102% **YoY)**, which dragged down earnings. In 9M20, total provisioning was up +69% YoY to reach VND2.9 tn.

The bank's LLR ratio reached 74% (+5ppt QoQ/+4ppt YoY) in 3Q20.

The reported NPL ratio was 2.14% (-2bps QoQ/+14bps YoY). Total legacy non-performing assets were VND71 tn (-1.8% QoQ/-8.7% YoY). We estimate that STB's total NPAs ratio decreased to 14.6% of the total assets as at 3Q20 (-40bps QoQ/-2.6ppt YoY).

Our view

We continue to view STB as a turnaround story. We expect the bank to continue resolve legacy NPAs over the long run although macro headwinds may be delaying this process. As a reminder, STB's NPA ratio peaked at 27.2% in 4Q17 and has declined consistently since.

Increased provisioning is prudent. STB continued to increase provisioning substantially in 3Q20, which we believe is the right approach to prepare for underlying asset quality deterioration due to the pandemic. In our view, reported NPLs do not fully reflect the underlying asset quality trends at any of the banks amid the SBV's forbearance policies.

STB trades at 0.9x 2020E P/B vs. the sector median of 1.3x. The stock price has soared by 21% in the past month, which we attribute to M&A chatter. As such, we would wait for a pullback before revisiting STB.

ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ARE LOCATED IN APPENDIX A.

Yuanta does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Appendix A: Important Disclosures

Analyst Certification

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

Ratings Definitions

BUY: We have a positive outlook on the stock based on our expected absolute or relative return over the investment period. Our thesis is based on our analysis of the company's outlook, financial performance, catalysts, valuation and risk profile. We recommend investors add to their position.

HOLD-Outperform: In our view, the stock's fundamentals are relatively more attractive than peers at the current price. Our thesis is based on our analysis of the company's outlook, financial performance, catalysts, valuation and risk profile.

HOLD-Underperform: In our view, the stock's fundamentals are relatively less attractive than peers at the current price. Our thesis is based on our analysis of the company's outlook, financial performance, catalysts, valuation and risk profile.

SELL: We have a negative outlook on the stock based on our expected absolute or relative return over the investment period. Our thesis is based on our analysis of the company's outlook, financial performance, catalysts, valuation and risk profile. We recommend investors reduce their position.

Under Review: We actively follow the company, although our estimates, rating and target price are under review.

Restricted: The rating and target price have been suspended temporarily to comply with applicable regulations and/or Yuanta policies.

Note: Yuanta research coverage with a Target Price is based on an investment period of 12 months. Greater China Discovery Series coverage does not have a formal 12 month Target Price and the recommendation is based on an investment period specified by the analyst in the report.

Global Disclaimer

© 2020 Yuanta. All rights reserved. The information in this report has been compiled from sources we believe to be reliable, but we do not hold ourselves responsible for its completeness or accuracy. It is not an offer to sell or solicitation of an offer to buy any securities. All opinions and estimates included in this report constitute our judgment as of this date and are subject to change without notice.

This report provides general information only. Neither the information nor any opinion expressed herein constitutes an offer or invitation to make an offer to buy or sell securities or other investments. This material is prepared for general circulation to clients and is not intended to provide tailored investment advice and does not take into account the individual financial situation and objectives of any specific person who may receive this report. Investors should seek financial advice regarding the appropriateness of investing in any securities, investments or investment strategies discussed or recommended in this report. The information contained in this report has been compiled from sources believed to be reliable but no representation or warranty, express or implied, is made as to its accuracy, completeness or correctness. This report is not (and should not be construed as) a solicitation to act as securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on such business in that jurisdiction.

Yuanta research is distributed in the United States only to Major U.S. Institutional Investors (as defined in Rule 15a–6 under the Securities Exchange Act of 1934, as amended and SEC staff interpretations thereof). All transactions by a US person in the securities mentioned in this report must be effected through a registered broker–dealer under Section 15 of the Securities Exchange Act of 1934, as amended. Yuanta research is distributed in Taiwan by Yuanta Securities Investment Consulting. Yuanta research is distributed in Hong Kong by Yuanta Securities (Hong Kong) Co. Limited, which is licensed in Hong Kong by the Securities and Futures Commission for regulated activities, including Type 4 regulated activity (advising on securities). In Hong Kong, this research report may not be redistributed, retransmitted or disclosed, in whole or in part or and any form or manner, without the express written consent of Yuanta Securities (Hong Kong) Co. Limited.

Taiwan persons wishing to obtain further information on any of the securities mentioned in this publication should contact:

Attn: Research Yuanta Securities Investment Consulting 4F, 225, Section 3 Nanking East Road, Taipei 104 Taiwan

Hong Kong persons wishing to obtain further information on any of the securities mentioned in this publication should contact:

Attn: Research Yuanta Securities (Hong Kong) Co. Ltd 23/F, Tower 1, Admiralty Centre 18 Harcourt Road, Hong Kong

Korean persons wishing to obtain further information on any of the securities mentioned in this publication should contact:

Head Office Yuanta Securities Building Euljiro 76 Jung-gu Seoul, Korea 100-845 Tel: +822 3770 3454

Indonesia persons wishing to obtain further information on any of the securities mentioned in this publication should contact:

Attn: Research PT YUANTA SECURITIES INDONESIA (A member of the Yuanta Group) Equity Tower, 10th Floor Unit EFGH SCBD Lot 9 Jl. Jend. Sudirman Kav. 52-53 Tel: (6221) - 5153608 (General)

Thailand persons wishing to obtain further information on any of the securities mentioned in this publication should contact:

Research department Yuanta Securities (Thailand) 127 Gaysorn Tower, 16th floor Ratchadamri Road, Pathumwan Bangkok 10330

Vietnam persons wishing to obtain further information on any of the securities mentioned in this publication should contact:

Research department Yuanta Securities (Vietnam) 4th Floor, Saigon Centre Tower 1, 65 Le Loi Boulevard, Ben Nghe Ward, District 1, HCMC, Vietnam

YUANTA SECURITIES NETWORK



YUANTA SECURITIES VIETNAM OFFICE

Head office: 4th Floor, Saigon Centre, Tower 1, 65 Le Loi Boulevard, Ben Nghe Ward, District 1, HCMC, Vietnam

Institutional Research

Matthew Smith, CFA

Head of Research

Tel: +84 28 3622 6868 (ext. 3815) matthew.smith@yuanta.com.vn

Tam Nguyen

Analyst (Property)

Tel: +84 28 3622 6868 (ext. 3874)

tam.nguyen@yuanta.com.vn

Tram Nguyen

Assistant Analyst

Tel: +84 28 3622 6868 (ext. 3872)

tram.nguyen@yuanta.com.vn

Institutional Sales

Huy Nguyen

Head of Institutional sales Tel: +84 28 3622 6868 (3808) Huy.nguyen@yuanta.com.vn

Binh Truong

Deputy Head of Research (O&G, Energy)

Tel: +84 28 3622 6868 (3845)

binh.truong@yuanta.com.vn

Tanh Tran

Analyst (Banks)

Tel: +84 28 3622 6868 (3874)

tanh.tran@yuanta.com.vn

Duyen Nguyen

Sales Trader

Tel: +84 28 3622 6868 (ext. 3890) duyen.nguyen@yuanta.com.vn